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The prostate-specific membrane antigen (PSMA) is a 100 kDa type II transmembrane glycoprotein 
with enzymatic activity similar to the family of zinc-dependent exopeptidases. This protein is of great 
medical and pharmacological interest as overexpression in prostate cells is related to the progression 
of prostate cancer; therefore, it represents an important target for the design of radiopharmaceuticals. 
The presence of two Zn2+ ions in the active site is crucial to the enzymatic activity and the design 
of high-affinity inhibitors. The amino acid residues coordinating these ions are highly conserved in 
PSMA orthologs from plants to mammals, and site-mutagenesis assays of these residues show a loss of 
enzymatic function or reduction of the kinetic parameters. In the present work, we performed molecular 
dynamics simulation of PSMA with the purpose of characterizing it energetically and structurally. We 
elucidated the differences of PSMA with its two Zn+2 ions as cofactors and without them in the free 
energy profile, and in four structural parameters: root mean square deviations and root mean square 
fluctuations by atom and amino acid residue, radius of gyration, and solvent accessible surface area.
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1. Introduction
Prostate cancer is a global problem since it is the second type 
of cancer with the highest incidence and the fifth with the 
highest number of deaths among men, while in Mexico it 
is the cancer type with higher incidence and mortality rate 
[1]. The Prostate-specific Membrane Antigen (PSMA) is a 
type II transmembrane glycoprotein of 100 kDa composed 
of 750 amino acids with at least three functions: hydrolytic 
NAALADase activity, folate hydrolase and dipeptidyl 
peptidase IV activity [2-4]. This protein is overexpressed 
in poorly differentiated and metastatic cells; consequently, 
it is considered an important indicator of prostate cancer 
and a target for the development of many inhibitors [5-6]. 
Recently, small molecule inhibitors (SMI) targeting PSMA 
have been developed; these are zinc- binding compounds 
linked to glutamate or a glutamate isomer. Urea-based 
SMI (Glu-urea-R) have demonstrated to specifically bind 
to PSMA and inhibit its activity in the LNCaP cell line. 
In such compounds, Glu-urea is the binding terminal and 
the R-group is the coupling terminal to other chemical 
groups such as a linker and a chelator associated with 
radionuclides [7-10].
The theranostic agents are based on the use of a 
radionuclide with the same PSMA-targeting ligands for 
therapy and diagnosis; for this purpose 177Lu, 225Ac, and 131I 
have been used. Particularly, 177Lu associated with PSMA-
617 has provided a safe and effective therapy in patients 
with metastatic castration-resistant prostate cancer [11-14]. 
PSMA-617 is a ligand conformed by a DOTA chelator 
(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid) 
conjugated with Glu-urea-Lys pharmacophore by a linker 
composed of two aromatic rings; it was designed for labeling 
with 177Lu and 68Ga to achieve high-quality image and 
efficient endotherapy [15-16]. 
Crystallographic structural studies of PSMA made 
possible to elucidate the interaction of the protein with the 
inhibitors. Structural information of PSMA is available only 
for the extracellular part of the protein (residues 44-750). It 
reveals that the protein exists as a symmetrical homodimer 
in vivo, each polypeptide monomer having three structural 
domains: a protease-like domain (residues 56-116 and 352-
591), an apical domain –also called the protease-associated 
domain- (residues 117-351), and the helical domain –
also called the C-terminal domain- (residues 592-750). 
[Figure. 1]. The active site of the protein contains a binuclear 
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Zn active site, catalytic residues, and a substrate-binding 
arginine-rich patch. A water ligand bridges the two zinc 
atoms, each coordinated by endogenous ligands: Zn(1) by 
His553 and Glu425, Zn(2) by His377 and Asp453, both 
atoms bounded by Asp387. Glu424 and Tyr552 have the 
catalytic function. A substrate/inhibitor-binding cavity with 
an area of about 1100 A2, and a diameter and deep of about 
20 Å, is formed in the interface between the three domains; 
this interface is considered large as it buries around 4600 A2. 
It is localized in the helical domain and is formed by two 
pockets, S1’(pharmacophore) and S1(non-pharmacophore). 
The cavity has an arginine patch (Arg463, Arg534, and 
Arg536) involved in the right orientation of the substrate 
for catalysis; it is aligned with the S1 which has a chlorine 
ion that keeps Arg534 in a conformation that allows the 
interaction with the substrate, while Arg536 and Arg463 
are flexible conferring tolerance to different chemical groups 
[Figure 2]. The “glutarate sensor” is responsible of detecting 
the absence or presence of glutamate in S1’ pocket and 
is formed by residues 692-704 together with Lys699 and 
Tyr700, which are also important for the specific binding of 
glutamate along with Arg210 in the apical domain [17-19].
The pharmacophore Glu-urea-Lys (iPSMA) [Figure 
3] is capable of binding with PSMA because it has three 
carboxylic acid groups. The glutamate-urea fraction of 
the inhibitor has a predisposition to be oriented towards 
S1’, and lysine is used for conjugation or derivatization, 
through the free amine, with a linker region or a chelating 
agent residing in S1. When both pockets are occupied, the 
hydrophobic contact (due to an aromatic agent) increases 
resulting in higher affinity [20,21].  The affinity to PSMA is 
due to the binding of glutamate by its α-carboxylate, which 
forms a bridge with the guanidinium group of Arg210, and 
hydrogen bonds with the hydroxide groups of Tyr552 and 
Tyr700, while the γ-carboxylate interacts with Lys699 and 
Ans257. The catalytic activity is carried out by Glu424, that 
extracts a proton from the water molecule situated between 
the zinc atoms and activates it [19,22]. The urea group 
serves as a zinc-binding group (ZBG) because the oxygen 
of the molecule interacts with Tyr552, His553, the active 
water molecule and Zn(1), while N groups form hydrogen 
bonds: N(1) with the main carbonyl chain of Gly-518 and 
the carboxylate of Glu-424, and N(2) with γ-carbonyl of 
Gly-518 [19, 23-24].
Figure 2. PSMA active site. Zinc ions are observed as red spheres, 
while the coordinating ligands of these ions are presented as 
magenta sticks. The substrate binding cavity is colored in blue, the 
arginine patch in orange and stabilizing ligands in green. 
Figure 1. PSMA structural domains. a) lateral view and b) superior view. The protease domain (56-116 and 352-591) is colored in red, the 
apical domain (117-351) in blue, and the helical domain in green (592-750).
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2. Method 
2.1 Theoretical model
To evaluate the structure of a biomolecule, we calculate the 
Root Mean Square Deviation (RMSD) between its atoms 
or residues, which allows comparing its molecular structure 
reached at any time t1, with respect to another structure 
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It is possible to analyze the flexibility of the protein 
through the oscillations of its amino acids, this property can 
be estimated through the Root Mean Square Fluctuation 
(RMSF) which can be calculated using
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Where T is the time over which the average is calculated.
To have a rough measure for the compactness of a 

























Where mi is the mass of atom i and ri the position of atom i 
with respect to the center of mass of the molecule.
The Solvent Accessible Surface Area (SASA) of a 
molecule is the region of its surface that has contact with 
the solvent and is, therefore, an indicator of the structural 
changes generated during the folding of the protein because 
SASA is directly proportional to its free energy.
2.2 Methodology 
For in silico analysis we used classical Molecular Dynamics 
(MD), the atomic coordinates for PSMA were extracted 
from the 1Z8L crystal structure in the Protein Data Bank. 
The protein was solvated using atomistic TIP3P water in a 
cubic box with at least 10 Å distance around the complex. 
We used the CHARMM force field. The two initial stages 
in the preparation of the systems, the stages of minimization 
and equilibration, were carried out using the NAMD2.6 
program. First, the systems were minimized for 10000 
steps, then thermalized for 10 ps at 300 K reinitializing 
the velocities every 20 ps. The equilibration of the systems 
was carried out with NAMD2.6 under periodic boundary 
conditions, time step 2 fs, cutoff 9 Å, Langevin damping 0.1/
ps. The long-range electrostatic interactions are accounted 
for using the particle mesh Ewald method, with a maximum 
grid spacing of 1.0 Å. Bond lengths are maintained rigid 
with the SHAKE. A final run of 100 ns was executed to 
assure that all properties, such as potential energy, van der 
Waals and electrostatic interactions, are in thermodynamic 
equilibrium. After 15 ns these quantities remain stable.
After the initial equilibration phase, the production 
simulation (100 ns) was carried out using platform ACEMD. 
This simulation was conducted in the NVT ensemble which 
resulted from the equilibration phase. We use a longer 
timestep of 4 fs thanks to the use of the hydrogen mass 
repartition scheme implemented in ACEMD. Coordinate 
snapshots were generated every 5 ps collecting a total of 
5000 conformational states for subsequent post-production 
analysis. The structural analysis presented in this work 
was held on 100 ns of simulation time. Molecular images 
displayed in this work were produced using PyMOL. 
All simulations referred were performed at our Cluster 
OLINKA, a platform designed to run molecular simulations 
to multiscale with GPUs. 
3. Results and Discussion
It is noteworthy that the active site is centered around the two 
zinc ions, and separates the S1’ and S1 pockets. One of the 
Zn2+ is considered the catalytic ion, coordinated by His553 
Figure 3. iPSMA structure (Glu-urea-Lys. a) The pharmacophore is composed by a glutamate (red), urea (green) and lysine (blue). b) Oxygen 
atoms are colored in red sticks, carbon colored in green sticks, hydrogen colored in white sticks and nitrogen colored in blue sticks. 
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and Glu425, and the other is the co-catalytic, coordinated 
by His377 and Asp453. Asp387 and a water molecule bridge 
the two zinc atoms thus forming a coordination sphere [19]. 
These five Zn-coordinating residues were implicated in site-
mutagenesis experiments resulting –with exception of the 
specific Asp387Asn substitution-, in no detectable enzymatic 
activity or an enzymatic activity too low for determination 
of kinetic parameters of PMSA mutants. The importance of 
these amino acids for PSMA activity is further noted in the 
fact that they are highly conserved in PSMA orthologs from 
plants to mammals [17,25].
Zn atoms are crucial for the enzymatic function of 
PSMA and for the design of inhibitors. In fact, the presence 
of a zinc-binding group is a fundamental feature in the 
design of high-affinity inhibitors of PSMA; among the 
substances that exhibit these groups are thiols, phosphonates, 
hydroxamates, phosphinates, phosphoamidates, ureas, and 
sulfonamides [19]. Once established the crucial role of Zn 
atoms, this work elucidates the differences in the free energy 
profile and four structural parameters of PSMA with the 
two Zn atoms as cofactors and without them: RMSD and 
RMSF by atom and amino acid residue, radius of gyration 
and SASA.
 
Figure 4. Radios of gyration (Rg) graphic over time showing the 
results from the simulation of the protein with and without the 
zinc atoms in the active site.
Radius of gyration gives an idea about the compactability 
of the molecule during time, since it provides an average 
of the expansion of its atoms with respect to its center of 
mass. When comparing the PSMA simulated with and 
without the zinc ions, it is visible that the PSMA with de 
zinc ions became more expanded over time than the other 
[Figure 4], consequently the zinc ions make the structure 
more receptive to the substrate/inhibitor by adopting an 
expanded geometrical conformation that allows its entrance. 
On the other hand, the RMSF (which is associated with 
flexibility) shows that the zinc coordinating amino acids of 
the Zn(1): His-553 and Glu-425, including Asp-387, are 
more flexible when simulated with the ions , while in the 
case of Zn(2): His-377 and Asp453 the flexibility is slightly 
higher [Figure 5]. This information is consistent with the 
fact that Zn(1) is consider the catalytic ion and as a result 
the coordinating amino acids need more flexibility for the 
interaction with the substrate/inhibitor, whilst Zn(2) is 
considered co-catalytic and the amino acids may not need 
to be so flexible [19].
(a)
(b)
Figure 5. Root Mean Square Fluctuation (RMSF) graphic. The 
RMSF is related to flexibility and is calculated for each of the amino 
acids conforming the PSMA, the resulting variations are shown. 
a) PSMA without zinc and b) PSMA with the zinc ions.
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Figure 6. Solvent Accesible Surface Area (SASA) graphic showing 
the results over time for the PSMA with and without zinc ions.
Figure 7. Root Mean Square Deviation (RMSD) graphic. The 
RMSD is related to structure stability of the atoms or residues over 
time of PSMA with and without the zinc ions.
In the RSMF, significant changes in flexibility between 
the two conditions are not observe in the substrate binding 
cavity (residues 687-704) and in the “glutarate sensor” 
(residues 692-704) indicating that the zinc atoms have no 
impact in these regions. The same situation was observed 
in the arginine patch (Arg-534, Arg-536 and Arg-463) 
meaning that the zinc ions do not play an important role 
in the right orientation of the substrate/inhibitor since 
the arginines are responsible of that task [17]. However, 
in Tyr-552 and Glu-424, to which catalytic activity and 
substrate recognition have been attributed respectively, 
more flexibility was observed in PSMA with the zinc ions 
confirming the significance of the interactions between the 
zinc ions and these amino acids in the active site [18]. The 
results from SASA are consistent with Rg, accordingly with 
the fact that the PSMA with the zinc ions is more expanded, 
it also has more solvent accessible surface area conferring 
it more free energy [Figure 6]. The RMSD shows that the 
PSMA with the zinc ions has more structural stability as it 
has less variations during time compared with the simulation 
without them. Therefore, the zinc ions are important for the 
structural stability of the protein [Figure 7]. 
4. Conclusions
In silico analysis of the PSMA showed that its structural 
stability has a direct and intrinsic dependence of its active 
center, in fact, the tests performed on the protein excluding 
the Zn atoms are conclusive to affirm that PSMA not only 
loses affinity to bind with molecules like inhibitors, also 
their energy capacity is diminished; however, there are 
regions between residues 100-122 and 640-730 that exhibit 
structural stability regardless of the absence of the Zn atoms. 
The tests carried out on PSMA with and without the heart 
of its active center, the Zn atoms, allowed us to conceive the 
protein as a closed system, with less energy and flexibility (in 
the absence of atoms). This situation is completely opposite 
when they are incorporated, which can be interpreted that 
PSMA behaves like a biological trap dependent on Zn. The 
CHARMM force field used was appropriate for modeling the 
PSMA interactions and can be adapted to study the processes 
involved in the active center in the presence of a urea-based 
inhibitor and, of course, a therapeutic radiopharmaceutical.
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